Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Lowered to Sell at StockNews.com

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Saturday. Separately, JPMorgan Chase & Co. decreased their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock […]

Related Keywords

Ohio ,United States , ,Capital Partners ,News Ratings For Enanta Pharmaceuticals Daily ,Enanta Pharmaceuticals Inc ,Jpmorgan Chase Co ,Barclays Plc ,Enanta Pharmaceuticals ,Institutional Trading Of Enanta Pharmaceuticals ,Voya Investment Management ,Enanta Pharmaceuticals Price Performance ,Vanguard Group Inc ,Analyst Recommendations For Enanta Pharmaceuticals ,Get Free Report ,Employees Retirement System ,Investment Management ,Enanta Pharmaceuticals Daily ,Nasdaq Enta ,Enta ,Medical ,Downgrade ,Stocknews Com ,